[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 28 days · First seen · Last updated

GSK oncology growth and strategic expansion

Overview

GSK has outlined a long-term growth strategy aiming for sales exceeding £40 billion, driven largely by its oncology portfolio. To support this target and offset upcoming patent expirations for HIV medicines, the company is implementing a simplification program intended to generate £1.9 billion in savings.

As part of its expansion in cancer therapies, GSK finalized an exclusive licensing agreement with a subsidiary of HUTCHMED for the experimental therapy HMPL-A830. This antibody-drug conjugate targets KRAS and EGFR to treat colorectal, pancreatic, and lung cancers. The deal includes a $110 million upfront payment to HUTCHMED, with potential milestone payments totaling up to $1.295 billion.

Entities

GSK · Bank of America · Gerdau S.A. · Rafael Gamboa Lopes · HUTCHMED

Timeline

  1. [BUSINESS] 2 sources
    GSK and HUTCHMED sign cancer therapy licensing deal

    GSK has secured global rights, excluding Greater China, for HUTCHMED’s experimental KRAS/EGFR-targeting cancer therapy HMPL-A830 in a deal worth up to $1.295 billion.

  2. [BUSINESS] 2 sources
    GSK targets £40B in sales through oncology growth and cost-savings

    GSK aims for over £40 billion in sales, driven by an oncology push and a £1.9 billion cost-savings plan to fund pipeline development.

Sources

24-ore.com · seekingalpha.com · stocknews.com · tmtpost.com